Patent ID: 8536188

Claim:
A method of treating a proliferative disorder which is selected from myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), said method comprising administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, to a subject in need thereof in accordance with a dosing regimen comprising at least one treatment cycle, wherein said metabolite is 2′-C-Cyano-2′-deoxy-β-D-arabino-pentafuranosylcytosine (CNDAC) and said treatment cycle comprises: (i) administering a therapeutically effective amount of sapacitabine or metabolite thereof for 3 consecutive days per week, for 2 weeks followed by; (ii) a rest period of from about 5 to about 15 days during which no sapacitabine or metabolite thereof is administered or until treatment-related toxicities are resolved, whichever is longer.